Volume 8, Issue 3 (7-2020)                   JoMMID 2020, 8(3): 93-97 | Back to browse issues page


XML Print


Bursa Yuksek Ihtisas Training and Research Hospital
Abstract:   (717 Views)
Introduction: Hepatitis A virus (HAV) infection poses a significant public health problem worldwide, especially in developing countries. This study investigated the effect of vaccination policies on the HAV seropositivity of Syrian immigrants and local Turkish people. Methods: The anti-HAV antibodies of 6007 patients, including 5613 (93.4%) Turks and 394 (6.6%) Syrian suspected of HAV infection, were analyzed by the chemiluminescent microparticle immunoassay (CMIA) method. Results: In our study, total anti-HAV positivity was higher in Turkish patients than in Syrian patients in the 0-9 age group, while in the 10-19, 20-29, and 30-39 age groups, the rate was higher in Syrians. Anti-HAV seropositivity was significantly higher in Turkish male patients than female patients. The young adult and adult age groups of Turks were more at risk of HAV infection, i.e., when the disease is symptomatic. Conclusion: Vaccination of young and young adult seronegative Turks and ensuring Syrian children's participation in the routine vaccination program implemented in our country is a requirement for preventing HAV infection.
Full-Text [PDF 813 kb]   (282 Downloads)    
Type of Study: Original article | Subject: Immune responses, deficiencies and vaccine candidates
Received: 2020/09/10 | Accepted: 2020/07/20 | Published: 2020/12/26

References
1. Alavian SM. Iraq: A Hot Zone for HAV Infection? Hepat Mmon. 2005; 5 (3): 53-6.
2. Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol. 2012; 4: 68-73. [DOI:10.4254/wjh.v4.i3.68]
3. Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat. 2008; 15 (2): 69-72. [DOI:10.1111/j.1365-2893.2008.01034.x]
4. WHO. The Global Prevalence of Hepatitis A Virus Infection and Susceptibility: A Systematic Review. Available from: URL: whqlibdoc.who.int/hq/2010/WHO_IVB_10.01_eng.pdf.
5. Sheila Sherlock & James Dooley. Diseases of the Liver and Biliary System, 11th edition, Blackwell Publishing. 2002: 273-6. [DOI:10.1002/9780470986820]
6. Raharimanga V, Carod JF, Ramarokoto CE, Chrétien JB, Rakotomanana F, Talarmin A, et al. Age-specific seroprevalence of hepatitis A in Antananarivo (Madagascar). BMC Infect Dis. 2008; 8: 78. [DOI:10.1186/1471-2334-8-78]
7. World Health Organization: Hepatitis A. Geneva: World Health Organization; 2000. WHO/CDS/CSR/EDC/2000-7.
8. Sohn YM, Rho HO, Park MS, Park JH, Choi BY, Ki M, et al. The changing epidemiology of hepatitis A in children and the consideration of active immunization in Korea. Yonsei Med J. 2000; 41: 34-9. [DOI:10.3349/ymj.2000.41.1.34]
9. Alborzi P, Alborzi AV, Boub R, Amoateng Y. Hepatitis A seroprevalence in Iranian children: implications for post exposure prophylaxis. 41st annual meeting of IDSA. October 9-12, 2003. San Diego.
10. Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc. 2006; 117: 227-38.
11. Lee SH, Kim SH, Park KO, Park JW, Chun SY, Lim SJ, et al. Prevalence of IgG anti-HAV in patients with chronic hepatitis B and in the general healthy population in Korea. Korean J Hepatol. 2010; 16 (4): 362-68. [DOI:10.3350/kjhep.2010.16.4.362]
12. Fahrni O, Posfay-Barbe KM, Wagner N. Immunization Against Hepatitis A in Migrant Children: Three Vaccination Strategies, A Retrospective Study. Pediatr Infect Dis J. 2020; 39 (2): 164-9. [DOI:10.1097/INF.0000000000002526]
13. Geçici Koruma. (2018a). Erişim adresi: http://www.goc.gov.tr/icerik3/gecici-koruma_363_378_4713, 06.12.2018a.
14. Alawa J, Zarei P, Khoshnood K. Evaluating the Provision of Health Services and Barriers to Treatment for Chronic Diseases among Syrian Refugees in Turkey: A Review of Literature and Stakeholder Interviews. Int J Environ Res Public Health. 2019; 16 (15): 2660. [DOI:10.3390/ijerph16152660]
15. Melhem NM, Miran J, Zaatari M, Awada H, Salibi NE, Ramia S. The changing pattern of hepatitis A in Lebanese adults. Int J Infect Dis. 2015; 30: 87-90. [DOI:10.1016/j.ijid.2014.10.007]
16. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect. 2004; 132: 1005-22. [DOI:10.1017/S0950268804002857]
17. Hanafiah KM, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geogr. 2011; 10: 57. [DOI:10.1186/1476-072X-10-57]
18. Luxemburger C, Dutta AK. Overlapping Epidemiologies of Hepatitis A and Typhoid Fever: the Needs of the Traveler. J Travel Med. 2005; 12: 12-21. [DOI:10.2310/7060.2005.12053]
19. Turky AM, Akram W, Al-Naaimi AS, Omer AR, Al- Rawi JR. Analysis of Acute Viral Hepatitis (A and E) in Iraq. Global Journal of Health Science. 2011; 3: 70-6. [DOI:10.5539/gjhs.v3n1p70]
20. Jacobsen KH. Wiersmab ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine. 2010; 28 (41): 6653-7. [DOI:10.1016/j.vaccine.2010.08.037]
21. Ceyhan M, Yildirim I, Kurt N, Uysal G, Dikici B, Ecevit C, et al. Differences in hepatitis A seroprevalence among geographical regions in Turkey: a need for regional vaccination recommendations. J Viral Hepat. 2008; 15: 69-72. [DOI:10.1111/j.1365-2893.2008.01034.x]
22. Jablonka A, Solbach P, Wöbse M, Manns MP, Schmidt RE, Wedemeyer H, et al. Seroprevalence of antibodies and antigens against hepatitis A-E viruses in refugees and asylum seekers in Germany in 2015. Eur J Gastroenterol Hepatol. 2017; 29 (8): 939-45. [DOI:10.1097/MEG.0000000000000889]
23. Koroglu M, Jacobsen KH, Demiray T, Ozbek A, Erkorkmaz U, Altindis M. Socioeconomic indicators are strong predictors of hepatitis A seroprevalence rates in the Middle East and North Africa.J Infect Public Health. 2017; 10 (5): 513-17. [DOI:10.1016/j.jiph.2016.09.020]
24. Melhem NM, Talhouk R, Rachidi H, Ramia S. Hepatitis A virus in the Middle East and North Africa region: a new challenge. J Viral Hepat. 2014; 21 (9): 605-15. [DOI:10.1111/jvh.12282]
25. Doganay M, Demiraslan H. Refugees of the Syrian Civil War: Impact on Reemerging Infections, Health Services, and Biosecurity in Turkey. Health Secur. 2016; 14 (4): 220-5. [DOI:10.1089/hs.2016.0054]
26. Melhem N, Kreidieh K, Ramia S. The Syrian refugees crisis brings challenges to the health authorities in Europe: hepatitis A virus is a case in point. Eur J Epidemiol. 2016; 31: 711-4. [DOI:10.1007/s10654-016-0163-5]
27. Bizri AR, Fares J, Musharrafieh U. Infectious diseases in the era of refugees: Hepatitis A outbreak in Lebanon. Avicenna J Med. 2018; 8 (4): 147-52. [DOI:10.4103/ajm.AJM_130_18]
28. Izadi M, Esfahani AA, Hassannia H, Jafari NJ, Najarkolaei FR, Rezaee-Zavareh MS. Seroprevalence of hepatitis A virus among Iranian soldiers.Gastroenterol Hepatol Bed BenchSpring. 2016; 9 (2): 100-4.
29. Gul HC, Avcı IY, Coşkun O, Ogur R, Basaran YH, Guney C, Besirbellioglu BA, et al. Anti-HAV seroprevalence in Turkish militarypersonnel and its relation with demographicproperties.Turk J Med Sci. 2009; 39 (5): 795-802.
30. Acikgoz A, Cimrin D, Kizildag S, Esen N, Balci P, Sayiner AA. Hepatitis A, B and C seropositivity among first-year
31. healthcare students in western Turkey: a seroprevalence study.BMC Infect Dis. 2020; 20 (1): 529.
32. Sharara SL, Kanj SS. War and infectious diseases: challenges of the Syrian civil war. PLoS Pathog. 2014; 10(10): e1004438. [DOI:10.1371/journal.ppat.1004438]
33. Cuthbert JA. Hepatitis A: Old and New. Clin Microbiol Rev. 2001; 14: 38-58. [DOI:10.1128/CMR.14.1.38-58.2001]
34. Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007; 5 (2): 79-84. [DOI:10.1016/j.tmaid.2006.04.004]